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Abstract
Background: We aimed at evaluating frequency and factors associated with late presentation and advanced HIV
disease and excess risk of death due to these conditions from 1985 to 2013 among naïve HIV infected patients
enrolled in the Italian MASTER Cohort.
Methods: All antiretroviral naive adults with available CD4+ T cell count after diagnosis of HIV infection were
included. Multivariable logistic regression analysis investigated factors associated either with late presentation or
advanced HIV disease. Probabilities of survival were estimated both at year-1 and at year-5 according to the
Kaplan-Meier method. Flexible parametric models were used to evaluate changes in risk of death overtime
according to late presentation and advanced HIV disease. The analyses were stratified for calendar periods.
Results: 19,391 patients were included (54 % were late presenters and 37.6 % were advanced presenters). At
multivariable analysis, the following factors were positively associated with late presentation: male gender
(OR = 1.29), older age (≥55 years vs. <25 years; OR = 7.45), migration (OR = 1.54), and heterosexual risk factor for HIV
acquisition (OR = 1.52) or IDU (OR = 1.27) compared to homosexual risk. Survival rates at year-5 increased steadily
and reached 92.1 % for late presenters vs. 97.4 % for non-late presenters enrolled in the period 2004–2009. Using
flexible parametric models we found a sustained reduction of hazard ratios over time for any cause deaths between
late and non-late presenters over time. Similar results were found for advanced HIV disease.
Conclusion: Screening polices need to be urgently implemented, particularly in most-at-risk categories for late
presentation, such as migrants, older patients and those with heterosexual intercourse or IDU as risk factors for HIV
acquisition. Although in recent years the impact of late presentation on survival decreased, about 10 % of patients
diagnosed in more recent years remains at increased risk of death over a long-term follow-up.
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Background
In 2011 consensus definitions of late presentation and
advanced HIV disease were formulated [1]. Late pre-
senters were defined as patients diagnosed with a CD4+
T cell count <350/mm3 or with an AIDS defining event.
About 50 % of HIV infected patients in Europe were late
presenters [1, 2]. Different HIV transmission patterns
were reported in late vs. non-late presenters, although
late presentation remains a major problem in any HIV
exposure groups [1, 3]. Indeed, rates of late presentation
in 2010–2013 were higher in Central Europe (49.8 %),
followed by Northern (48.8 %), Southern (45.8 %) and
Eastern Regions (38.3 %), especially among intravenous
drug users (IDUs) [3, 4].
Late presentation is associated with a greater risk of
polypharmacy, drug non adherence and suboptimal viro-
logical and immunological effectiveness of antiretroviral
therapy [5–7]. From a pharmaco-economical point of
view, late presentation increases costs for health care [5].
Patients presenting late show higher rates of AIDS and
death when compared with subjects presenting earlier
[6, 8, 9], especially during the first year after HIV diag-
nosis [1]. Moreover, from a public health perspective,
people presenting late were spending longer time being
unaware of their status, did not start any combination
antiretroviral therapy (cART), which is effective in redu-
cing HIV RNA (thereby reducing the risk of transmis-
sion by >95 % [10]), so late presentation contributes to
enhance rates of HIV transmission [11]. Indeed, some
studies reported that community HIV RNA concentra-
tions were correlated with incedence of new HIV diag-
noses in specific contexts (e.g., among IDUs or men who
have sex with men, MSM) [12, 13]. For these reasons,
the World Health Organization (WHO), promotes initia-
tives to increase HIV testing and retention into care,
aimed at reducing rates of late diagnosis and conse-
quently HIV transmission [14], but in reality such cam-
paigns are poorly implemented in some contexts.
In Italy, people presenting late were older (age >50 years),
migrants, and more frequently were diagnosed in the
Southern-Central Regions [15, 16]. Italian late presenters
acquired HIV infection most frequently by heterosexual
contacts [15, 16], and secondly by IDU, whereas in other
European Countries higher rates of late presenters were
reported among IDUs [17].
Until now, national studies evaluated late presentation
in a limited period [15, 18, 19]. Moreover, regional analyses
were performed along a extended time of observation, but
sample was not representative of the national scenario of
late presentation and size of the population did not allow
to perform a stratified analysis by calendar periods [20,
21]. So, we believe that the available results are not power-
ful enough to drive preventative strategies and monitor
the effects of late presentation on patient survival.
The aim of this study was to study late presentation in
a large national Italian cohort from the beginning of the
epidemic in Italy to present days. In particular, we evalu-
ated frequency of late presentation over calendar years
and associated factors. We further examined whether
late presentation was associated with patient survival,
and if differences in the mortality rates between late pre-
senters and non late presenters improved overtime to
have indications on possible gaps in HIV disease man-
agement that may be still present in these patients.
Methods
HIV positive patients enrolled in the Italian MASTER
(Standardized Management of Antiviral Therapy) Cohort
[22] from January 1985 to December 2013 were selected.
Epidemiological, virological, immunological, demograph-
ical and clinical data from all patients in the Cohort are
stored and annually updated into a common database
(Health & Notes 3.5®, Healthware S.p.A., Naples, Italy).
All antiretroviral treatment-naïve patients with avail-
able CD4+ T cell count at enrolment were included in
the study. CD4+ T cell count at enrolment was defined
as CD4+ T cell count closest to and within 6 months
since enrolment. Viral load was available since 1996 and
defined as HIV RNA closest to or within 30 days since
enrolment, including only treatment-naïve subjects at
enrolment.
Late presentation refers to people diagnosed with HIV
with a CD4+ T cell count below 350/mm3 or with an
AIDS defining event regardless of the CD4+ T cell count
in the 6 months following HIV diagnosis. Advanced HIV
disease refers to people diagnosed with HIV with a CD4
+ T cell count below 200/mm3 or with an AIDS defining
event, regardless of CD4+ T cell count in the 6 months
following HIV diagnosis. HCV co-infection was defined
on the basis of positive HCV antibodies.
Vital status and date of death were ascertained
through clinical charts, and through a record-linkage
with Local Health Authority mortality registers in about
one third of patients.
Statistical analysis
Follow-up was determined from enrolment to 31
December 2013 or last follow-up visit, or death, which-
ever occurred first.
Differences in demographic and clinical features of pa-
tients were tested using common statistical methods for
comparisons of means and proportions. Associations of
demographical and clinical features with late presenta-
tion and advanced HIV disease were investigated using a
logistic regression model, providing estimates of the
odds ratios (ORs) as measures of association and their
95 % confidence intervals (95 % CIs). We adjusted the
models for the following a priori confounders: gender,
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age at enrolment, country of origin, HIV exposure cat-
egory and period of enrolment as covariates. Separate
analyses have been performed in patients presenting at
different time periods. The probabilities of survival were
estimated at year-1 and at year-5 according to the
Kaplan-Meier methods according to late presentation,
advanced HIV disease and time periods. The survival
curves were compared using the log-rank test. As sensi-
tivity analysis, we calculated probabilities of survival at
year-1 and at year-5 applying an inverse probability
weighted method to the Kaplan-Meier curves in order to
adjust for selection bias due to lost to follow-up
(365 days and over since their last visit or exams). Cubic
splines were modeled using flexible parametric models
[23–25] to evaluate changes of risk of death overtime
between late presenters and non late presenters and be-
tween subjects with and without advanced HIV disease.
The models were adjusted for a priori confounders, in-
cluding age, gender, country of origin and HIV exposure
category. The results were expressed in terms of hazard
ratios (HRs) over time and their 95%CIs.
All statistical tests were two-sided, assuming a level of
significance of 0.05 and were performed using Stata soft-
ware version 12.0 (Stata Corp, College Station, TX, USA).
Results
Overall population
19,391 patients were included in the study contributing
143,097 person-years (median 5.2 years of follow-up).
Among these patients, 10,486 (54.1 %) were late pre-
senters and 7,291 (37.6 %) had advanced HIV disease at
presentation. Table 1 reports the main demographic, epi-
demiological and clinical characteristics.
Percentages of late presenters increased from 1985–
1991 (39.2 %) to 1992–1997 (58.7 %) and then remained
stable over time (56.9 % in 2010–2013). Likewise, the
prevalence of advanced HIV disease at presentation in-
creased from 1985–1991 (26.9 %) to 1992–1997 (42.1 %),
and then showed a modest reduction up to 2010–2013
(38.7 %). The cumulative probability of loss to follow-up
at year-3 was 21.4 % (95 % CI 20.8-22.0 %).
Most patients were Italians (89.4 %) and males
(74.8 %). Frequency of males ranged from 77.7 to 71.8 %
among observational periods. Mean age was 34.8 years
(standard deviation, SD 9.8). Major risk factors for HIV
acquisition were IDU (42.6 %) and sexual transmission
(15.8 % MSM, 33.7 % heterosexuals). In particular, for
males the major risk factors were in the order: IDU
(46.7 %), heterosexual transmission (24.8 %) and MSM
(21 %). For females the major risk factors were: hetero-
sexual transmission (59.7 %) and IDU (30.5 %). Fourty-
eight percent patients had HCV co-infection; while
13.5 % patients were co-infected by HBV. Prevalence of
HCV co-infection decreased steadily, from 79.2 % in
1985–1991 to 20.3 % in 2010–2012, whereas prevalence
of HBV remained stable between 10 % and 19.1 %
throughout the entire study period.
Considering cART, no prescription, two nucleoside
reverse-transcriptase inhibitors plus one non-nucleoside
reverse-transcriptase inhibitors (2NRTIs + NNRTI) and
2NRTIs plus one protease inhibitor either boosted or
unboosted by ritonavir (2NRTIs + PI ± r) in the periods
under study were, respectively: a) 1985–1991: 51, 0 and
0 %, b) 1992–1997: 45.6, 3.2 and 15.5 %; c) 1998–2003:
5.2, 29.9 and 41.6 %; d) 2004–2009: 1.6, 31.2 and 45.7 %;
e) 2010–2013: 0.4, 16.5 and 37.7 %.
Table 1 describes demographic and clinical features ac-
cording to late presentation. Subjects with foreign ori-
gins had more frequently late presentation than Italians
(62.2 vs. 52.9 %, p<0.001). Patients presenting late were
older than non-late presenters [mean age of late pre-
senters was 37 years (SD 9.9) vs. 32 years (SD 8.9) for
non late presenters]. Mean CD4+ T cell count was 171/
mm3 (SD 137.4) and 644.4/mm3 (SD 275) in late and
non-late presenters, respectively. Subjects with hetero-
sexual risk factor had a late presentation more fre-
quently than MSM and IDUs (60.8 vs. 52.2 % and
48.5 %, p < 0.001). Prevalence of late presenters among
MSM decreased from 58.7 % in 1985–1991 to 44.9 % in
2010–2013, whereas, among subjects with heterosexual
intercourse as risk factor for HIV acquisition, it increased
from 37.2 % in 1985–1991 to 58.2 % in 1992–1997 and to
65.7 % in 2010–2013. HCV co-infected patients were less
frequently late presenters than non-HCV co-infected (44.9
vs. 54.8 %, p<0.001), whereas HBV co-infected had an
higher prevalence of late presentation than individuals not
co-infected by HBV (55.3 vs. 49.2 %, p<0.001).
Factors associated with late presentation
As shown in Table 2, when compared with MSM, the
following categories were more likely to present late:
people of male gender (OR = 1.29), with older age
(≥55 years vs. <25 years; OR = 7.45), migrants (OR =
1.54), heterosexuals (OR = 1.52), and IDUs (OR = 1.27).
In the time-stratified analysis, statistically significant
associations between late presentation and male gender
were found in all periods, but not in the more recent
years (2004–2009 and 2010–2013). Age >25 years and
migration were associated with late presentation in any
time periods. Heterosexual transmission and IDU com-
pared to MSM were associated with higher risk of late
presentation in almost all time periods.
We also found associations when we evaluated factors
related with advanced HIV disease (see Additional file 1:
Table S1). In the overall population, advanced HIV
disease was positively associated with male gender [OR =
1.47, 95%CI 1.35–1.60], older age at enrolment (≥55 years
vs. <25 years; OR = 9.59, 95%CI 7.83–11.75), migration
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Table 1 Characteristics of subjects at enrolment according to late presentation
Subjects’ characteristics No Yes Total P value
n (%)* n (%)a n (%)b
Total 8905 10486 19391
Gender
Male 6477 (44.7) 8022 (55.3) 14499 (74.8) <0.001
Female 2428 (49.6) 2464 (50.4) 4892 (25.2)
Age at enrolment (years)
< 25 1869 (71.9) 729 (28.1) 2598 (13.4) <0.001
25–34 4362 (49.3) 4478 (50.7) 8840 (45.6)
35–44 1863 (36.2) 3290 (63.9) 5153 (26.6)
45–54 602 (30.8) 1355 (69.2) 1957 (10.1)
≥ 55 209 (24.8) 634 (75.2) 843 (4.3)
Mean age, years (SD) 32.1 (8.9) 37.0 (9.9) 34.8 (9.8) <0.001
Mean CD4 T+ cell count//mm3 (SD) 644.4 (275) 171.1 (137.4) 403.1 (320.4) <0.001
Period of enrolment
1985–1991 2612 (60.8) 1681 (39.2) 4293 (22.1) <0.001
1992–1997 2010 (41.3) 2855 (58.7) 4865 (25.1)
1998–2003 1727 (40.6) 2528 (59.4) 4255 (21.9)
2004–2009 1642 (42.5) 2217 (57.5) 3859 (19.9)
2010–2013 914 (43.1) 1205 (56.9) 2119 (10.9)
Country of origin
Availableb 8738 (98.1) 10210 (97.4) 18948 (97.7) <0.001
Italy 7996 (47.1) 8991 (52.9) 16987 (89.4)
Others 742 (37.8) 1219 (62.2) 1961 (10.3)
HIV exposure category
Availableb 8156 (91.6) 9528 (90.9) 17684 (91.2) <0.001
MSM 1333 (47.8) 1455 (52.2) 2788 (15.8)
IDUs 3879 (51.5) 3654 (48.5) 7533 (42.6)
Heterosexuals 2337 (39.2) 3620 (60.8) 5957 (33.7)
MSM-IDUs 60 (57.1) 45 (42.9) 105 (0.6)
Heterosexuals-IDUs 256 (41.0) 368 (59.0) 624 (3.5)
Haemophilia/Perinatal transmission 26 (53.1) 23 (46.9) 49 (0.3)
Unknown 32 (48.5) 34 (51.5) 66 (0.4)
Others 233 (41.5) 329 (58.5) 562 (3.2)
Viral load at enrolmentc
Availableb 3678 (41.3) 5348 (51.0) 9026 (46.5) <0.001
Mean HIV RNA, log10 copies/ml (SD) 4.2 (1.0) 4.9 (0.9) 4.6 (1.0)
Hepatitis C co-infection
Availableb 6913 (77.6) 6923 (66.0) 13836 (71.4) <0.001
No 3250 (45.2) 3942 (54.8) 7192 (52.0)
Yes 3663 (55.1) 2981 (44.9) 6644 (48.0)
Hepatitis B co-infection
Availableb 7832 (88.0) 7836 (74.7) 15668 (80.8) <0.001
No 6889 (50.8) 6669 (49.2) 13558 (86.5)
Yes 943(44.7) 1167 (55.3) 2110 (13.5)
aRow percentages bcolumn percentages. cViral load is available since 1996 and defined as viral load closest to and within 30 days since enrolment, including only
treatment-naïve subjects at enrolment. CD4+ T cell count at enrolment is defined as CD4+ T cell count closest to and within 6 months since enrolment. IDUs Intravenous
drug users, MSM Men who have sex with men
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Table 2 Multivariable logistic regression model: association of demographical and clinical features with late presentation according to observation period
Total period (n = 17333) 1985–1991 (n = 4254) 1992–1997 (n = 4614) 1998–2003 (n = 3892) 2004–2009 (n = 3142) 2010–2013 (n = 1431)
Variable Category ORs (95 % CI) P value ORs (95 % CI) P value ORs (95 % CI) P value ORs (95 % CI) P value ORs (95 % CI) P value ORs (95 % CI) P value
Gender Male vs Female 1.29 (1.19–1.40) <0.001 1.18 (1.00–1.40) 0.054 1.45 (1.25–1.69) <0.001 1.31 (1.12–1.54) 0.001 1.17 (0.97–1.42) 0.099 1.10 (0.82–1.46) 0.525
Age at
enrollment
<25 Ref. Ref. Ref. Ref. Ref. Ref.
25–34 2.44 (2.21–2.70) <0.001 2.55 (2.20–2.97) <0.001 2.99 (2.42–3.69) <0.001 2.52 (1.88–3.39) <0.001 1.48 (1.10–2.00) 0.009 1.58 (1.04–2.40) 0.032
35–44 4.11 (3.65–4.61) <0.001 5.33 (4.04–7.02) <0.001 4.84 (3.82–6.14) <0.001 4.44 (3.29–6.01) <0.001 2.49 (1.84–3.35) <0.001 2.65 (1.74–4.03) <0.001
45–54 5.79 (4.98–6.74) <0.001 5.04 (2.90–8.73) <0.001 5.20 (3.68–7.35) <0.001 7.70 (5.35–11.08) <0.001 3.57 (2.56–4.99) <0.001 3.75 (2.39–5.90) <0.001
≥55 7.45 (6.06–9.16) <0.001 21.65 (6.07–77.22) <0.001 8.06 (5.19–12.53) <0.001 10.08 (6.27–16.19) <0.001 4.19 (2.76–6.36) <0.001 3.98 (2.29–6.94) <0.001
Country of
Origin
Others vs Italy 1.54 (1.38–1.73) <0.001 1.91 (1.04–3.49) 0.036 0.94 (0.67–1.33) 0.742 1.53 (1.25–1.88) <0.001 1.48 (1.21–1.81) <0.001 1.52 (1.15–2.03) 0.004
HIV exposure
category
MSM Ref. Ref. Ref. Ref Ref. Ref.
IDUs 1.27 (1.15–1.40) <0.001 0.59 (0.43–0.80) 0.001 1.44 (1.18–1.76) <0.001 1.27 (1.04–1.56) 0.017 1.18 (0.93–1.50) 0.172 2.12 (1.30–3.47) 0.003
Heterosexuals 1.52 (1.37–1.69) <0.001 0.54 (0.37–0.77) 0.001 1.44 (1.15–1.81) 0.002 1.69 (1.39–2.06) <0.001 1.73 (1.43–2.10) <0.001 1.89 (1.42–2.50) <0.001
MSM-IDUs 0.89 (0.59–1.34) 0.584 0.44 (0.21–0.93) 0.032 0.69 (0.34–1.38) 0.294 0.86 (0.32–2.30) 0.77 2.47 (0.61–9.97) 0.204 2.89 (0.25–32.84) 0.393
Heterosexuals-IDUs 1.88 (1.56–2.26) <0.001 1.47 (0.95–2.27) 0.085 2.39 (1.73–3.29) <0.001 1.42 (0.93–2.17) 0.106 0.67 (0.40–1.11) 0.121 1.07 (0.4–2.88) 0.896
Haemophilia /Perinatal
transmission
0.84 (0.36–1.09) 0.574 0.26 (0.09–0.76) 0.014 0.55 (0.17–1.72) 0.302 1.73 (0.32–9.40) 0.528 1.43 (0.08–24.65) 0.808 2.01 (0.43–9.38) 0.373
Unknown 1.05 (0.42–1.10) 0.856 0.95 (0.14–6.53) 0.958 1.21 (0.43–3.36) 0.718 1.89 (0.16–22.73) 0.617 1.50 (0.52–4.36) 0.456 0.79 (0.35–1.81) 0.582




1992–1997 1.56 (1.43–1.71) <0.001
1998–2003 1.29 (1.16–1.43) <0.001
2004–2009 1.14 (1.02–1.28) 0.026
2010–2013 1.17 (1.01–1.35) 0.032
The associations of demographical and clinical features with late presentation were investigated using a logistic regression model, providing estimates of the odds ratios (ORs) as measures of association. Separate












(OR = 1.39, 95%CI 1.24–1.56) and heterosexual inter-
course (OR = 1.44, 95%CI 1.30–1.60) or IDU (OR = 1.17,
95%CI 1.05–1.29) as risk factor for HIV acquisition com-
pared to MSM.
Survival analysis stratified along calendar years
Survival estimates for people presenting late compared
to non-late presenters were 73.9 vs. 99.6 % at year-1
and 35.8 vs. 93.3 % at 5-year in 1985–1991 (log-rank
test p<0.001 for both comparisons). Survival rates in-
creased steadily in 1992–1997 and in 1998–2003 either
for late presenters or for non late presenters. Survival
rates at year-1 and at year-5 reached 95.9 and 92.1 % for
late presenters vs.99.2 and 97.4 % for non-late pre-
senters in 2004 to 2009 but differences between late and
non late presenters remained significant for both com-
parisons (p <0.001). (Fig. 1a). Similarly, a better survival
was observed in subjects presenting without advanced
HIV disease than in subjects with advanced HIV disease
(log-rank test p< 0.001 for the whole period) (Fig. 1b).
Survival rates at year-1 and at year-5 increased in sub-
jects without advanced HIV disease at presentation
from 99.5 and 90.8 % in 1985–1991 to 99 and 96.6 % in
2004–2009. For subjects with advanced HIV disease at
presentation, survival rates at year-1 and at year-5 in-
creased from 62.8 and 17.2 % in 1985–1991 to 94.6 and
90.8 % in 2004–2009. When we calculated the survival
estimates at year-1 and at year-5 using a model weighted
for losses to follow-up, the survival estimates for late-
presenters and subjects with advanced HIV disease were
lower in 1985–1991 and in 1992–1997 than non-
weighted survival estimates (see Additional file 1: Table
S2). Late presentation and advanced HIV disease were
also evaluated in multivariate flexible parametric models
with restricted cubic-splines for the HRs of these vari-
ables, which showed a sustained reduction of HRs over
time in all periods (Fig. 2). Moreover, when mortality at
year-1 was studied in the same models, HRs for late pre-
senters vs. non late presenters were 70.4 (95%CI 46–108)
in 1985–1991, 22.1 (95%CI 13.8–35.4) in 1992–1997, 5.4
(95%CI 3.5–8.3) in 1998–2003 and 2.5 (95%CI 1.5–4.3) in
2004–2009.
Discussion
In the present study we evaluated factors associated with
late presentation and compared risk of death for late
presenters with risk of death for non late presenters
from 1985 to 2013 in a large cohort of drug naïve HIV
infected subjects enrolled in Italy. These analyses were
also stratified for calendar periods.
Overall, proportion of late presentation and advanced
HIV disease were 54 and 38 %, respectively. Late diagno-
ses were more frequent in the period from 1992 to 2009.
Proportion of late presenters in our cohort is in line with
previous studies reported by Collaboration of Observa-
tional HIV Epidemiological Research Europe Study
(COHERE) for Southern Europe in the same time frame
[1, 3] and by other recent European and Italian studies
[15–21, 26–29]. This was not unexpected because the
Italian MASTER Cohort is one of the main contributors
to COHERE. Also, profile of people presenting late was
similar to previous European and Italian estimates [1, 3,
15]. Indeed, patients presenting late were mostly males,
migrants and older than individuals who presented earl-
ier. Only in specific contexts female patients accounted
for the majority of late presentations, especially because
of the female component of the migrant population
coming from Sub Saharian Africa [30–32].
We assessed evolution of factors associated with late
presentation along calendar periods. In parallel with a
decrease of late presentation among MSM over calendar
periods, there was a increase in prevalence of late presen-
tation among heterosexuals, and heterosexual transmis-
sion was one of the main risk factors for late presentation
from 1992 to 2013. So, we could hypothesize that infor-
mation and screening polices were quite successful among
MSM communities, although a increase of HIV diagnoses
in young MSM has been recently reported [33]. The most
likely explanation is that older MSM had personal experi-
ences of HIV complications occurring in friends, partners
or members of the same community, while younger MSM
may only be informed through preventative campaigns in
the field. Although the youngest MSM may have not been
involved or not respondent to these campaigns as demon-
strated by an increase of new HIV diagnoses in the same
population in the latest years [33], the level of information
in MSM may be higher than in other populations. More-
over, information campaigns in MSM were proven to be
successful [34], while heterosexuals did not regularly prac-
tice safe sex even if they were well informed about preven-
tion of HIV or other sexually transmitted diseases [35]. It
is difficult to explain this possible discrepancy but general
differences in the cultural level or background of experi-
ences may play a role.
Compared to MSM, IDUs had a greater risk of late
presentation, consistently in all calendar periods. This
result has to be referred to syringe exchange (especially
in Italy where programs to provide syringes to IDUs are
lacking). However, even in IDU populations the risk of
HIV acquisition appeared to be more linked with hetero-
sexual intercourses than with IDU by itself [36]. Also,
use of recreational drugs (even not intravenous) may be
responsible for a increased risk of transmission through
sexual intercourses independently from gender and types
of sexual relationships. Therefore, further behavioral
studies should be conducted to understand the actual
ways of HIV transmission and behaviors that may en-
hance this risk.
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Fig. 1 Survival rates from 1985 to 2009 according to late presentation (a) and advanced HIV disease (b)
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Overall, the risk of late presentation was frequently as-
sociated with heterosexual transmission in more recent
years. Lack of knowledge and underestimation of HIV
transmission through this route probably contributed to
a late diagnosis, especially among heterosexuals. Indeed,
the main reason for late HIV testing reported by hetero-
sexual late presenters was unawareness of risk or un-
awareness of symptoms of HIV [32]. People presenting
late often declare that they were not ill, although the
majority of them were symptomatic during the year pre-
ceding HIV diagnosis and consulted a physician for
these symptoms [32]. In other cases (as among foreign
patients, women and IDUs), socioeconomic status and
poor access to health care may have contributed to late
presentation [37, 38]. At the same time, it is possible
that some other factors may contribute to decreased use
of condoms, either among heterosexuals or MSM, as al-
cohol abuse and/or illicit drug use. So, informative cam-
paigns for prevention and early diagnoses should be
targeted to persons with any risk behaviors (including
heterosexual individuals) rather than to the classical risk
categories, such as IDUs or MSM.
In our study we found that survival rates at year-1 and
at year-5 increased steadily either for late presenters or
for non late presenters. However, survival was always
poorer in late presenters compared to non late pre-
senters in all time periods. Using flexible parametric
models we found that the excess mortality rate in late
presenters was highest immediately after diagnosis and
then declined, mostly in farthest years (from 1985 to
1998). Similar results were found for people with ad-
vanced HIV disease. In more recent years, improved
standards of care and more effective antiretroviral ther-
apies were introduced [39], so this improved clinical out-
comes even in patients who presented late. This
consideration is important because if the definition of
late presentation is applied to classify patients by clinical
risk, the existing definition may be anachronistic and
should be somehow revised. Alternatively, the improved
clinical outcome in late presenters may be due to differ-
ent composition of the patient cohort across calendar
periods. If this is true, the definition should be made
more specific in different categories of patients. Not-
withstanding these considerations, late presentation
should be avoided anyway because it has a strong nega-
tive impact on test-and-treat strategies promoting HIV
transmission. Also, anticipation of therapy at higher
CD4 T cell counts improves patient survival as demon-
strated by the START study [40], so more recent guide-
lines recommend to start cART irrespectively of CD4 T
cell count at diagnosis [41]. Moreover, earlier cART re-
duces morbidities [40], which was not an outcome of
our study.
Several limitations of our work should be considered.
First, we likely underestimated late presenters in farthest
periods, because people diagnosed at that time may have
died after the access to the hospital and not survived
long enough to be enrolled in the cohort. Second, transi-
ent low CD4 T+ cell count in patients with recent infec-
tions may lead to overestimation of late presenters,
classified according to the consensus definition [42].
However, percentage of patients with recent infection in
our cohort was very small and did not influence the re-
sults. Indeed, people with a diagnosis of acute or recent
infection were very few in the cohort (<1 % in any
Fig. 2 Hazard ratios over time for late presentation (a) and advanced
HIV disease (b) using flexible parameter models
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calendar periods under study). Furthermore, our cohort
was affected by a high cumulative probability of loss to
follow-up at year-3. This high rate of loss to follow-up is
common in retrospective cohort studies, however. Selec-
tion bias due to loss to follow up represents a threat to
the internal validity of the survival estimates and un-
adjusted model could overestimated the survival esti-
mates. In our paper we tried to mitigate this selection
bias presenting also inverse probability-of-censoring
weighted survival estimates.
Conclusions
In conclusion, late presentation affected over 50 % of
HIV diagnoses in our cohort. Combination antiretroviral
therapy and improved health care contributed to reduce
short and long term mortality among late presenters in
more recent years. Interestingly, we found that the ex-
cess risk of death due to late presentation on overall
mortality (at year-1 and at year-5) decreased over calen-
dar years. However, statistically significant differences in
survival rates between late and non late presenters were
found in all time periods. IDUs, people with heterosex-
ual intercourses, migrants and older patients were more
at risk of presenting late in our cohort. Similar associa-
tions were found for advanced HIV disease. However, re-
sults obtained in the overall populations have to be
carefully interpreted, because factors associated with late
presentation may change over time, as showed by our
analysis stratified by calendar years. Further strategies to
encourage and facilitate earlier diagnosis are needed:
widespread testing, reaching vulnerable populations,
identify and fight against stigma. Increasing HIV testing,
information campaigns about HIV risk factors and im-
provement of the test-and-treat strategy recommended
by in the Italian Guidelines only recently [41] will hope-
fully reduce rates of HIV transmission and late presenta-
tions. So our results should be interpreted as a baseline
analysis for further monitoring of patient characteristics
at diagnosis and clincal outcomes over the long term.
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